A 0 1 0 1 O
second 2 8 2 8 O
post 9 13 9 13 B-treatment
- 13 14 13 14 I-treatment
treatment 14 23 14 23 I-treatment
biopsy 24 30 24 30 I-treatment
will 31 35 31 35 O
be 36 38 36 38 O
offered 39 46 39 46 O
but 47 50 47 50 O
will 51 55 51 55 O
not 56 59 56 59 O
be 60 62 60 62 O
mandated 63 71 63 71 O

ALT 0 3 72 75 B-clinical_variable
( 4 5 76 77 I-clinical_variable
SGPT 5 9 77 81 I-clinical_variable
) 9 10 81 82 I-clinical_variable
≤ 11 12 83 84 O
2.5 13 16 85 88 B-upper_bound
X 17 18 89 90 I-upper_bound
institutional 19 32 91 104 I-upper_bound
upper 33 38 105 110 I-upper_bound
limit 39 44 111 116 I-upper_bound
of 45 47 117 119 I-upper_bound
normal 48 54 120 126 I-upper_bound

AST 0 3 127 130 B-clinical_variable
( 4 5 131 132 I-clinical_variable
SGOT 5 9 132 136 I-clinical_variable
) 9 10 136 137 I-clinical_variable
≤ 11 12 138 139 O
2.5 13 16 140 143 B-upper_bound
X 17 18 144 145 I-upper_bound
institutional 19 32 146 159 I-upper_bound
upper 33 38 160 165 I-upper_bound
limit 39 44 166 171 I-upper_bound
of 45 47 172 174 I-upper_bound
normal 48 54 175 181 I-upper_bound

ECOG 0 4 182 186 B-clinical_variable
Performance 5 16 187 198 I-clinical_variable
Status 17 23 199 205 I-clinical_variable
0 24 25 206 207 B-lower_bound
- 25 26 207 208 O
1 26 27 208 209 B-upper_bound

Hemoglobin 0 10 210 220 B-clinical_variable
≥ 11 12 221 222 O
10.0 13 17 223 227 B-lower_bound
g 18 19 228 229 I-lower_bound
/ 19 20 229 230 I-lower_bound
dl 20 22 230 232 I-lower_bound

History 0 7 233 240 O
of 8 10 241 243 O
allergic 11 19 244 252 O
reactions 20 29 253 262 O
attributed 30 40 263 273 O
to 41 43 274 276 O
compounds 44 53 277 286 B-allergy_name
of 54 56 287 289 I-allergy_name
similar 57 64 290 297 I-allergy_name
chemical 65 73 298 306 I-allergy_name
or 74 76 307 309 I-allergy_name
biologic 77 85 310 318 I-allergy_name
composition 86 97 319 330 I-allergy_name
to 98 100 331 333 I-allergy_name
nab 101 104 334 337 I-allergy_name
- 104 105 337 338 I-allergy_name
paclitaxel 105 115 338 348 I-allergy_name
, 115 116 348 349 O
carboplatin 117 128 350 361 B-allergy_name
, 128 129 361 362 O
pembrolizumab 130 143 363 376 B-allergy_name
, 143 144 376 377 O
or 145 147 378 380 O
other 148 153 381 386 B-allergy_name
agents 154 160 387 393 I-allergy_name
used 161 165 394 398 O
in 166 168 399 401 O
this 169 173 402 406 O
study 174 179 407 412 O

Patients 0 8 413 421 O
active 9 15 422 428 B-chronic_disease
infection 16 25 429 438 I-chronic_disease
requiring 26 35 439 448 O
intravenous 36 47 449 460 O
systemic 48 56 461 469 B-treatment
therapy 57 64 470 477 I-treatment

Patients 0 8 478 486 O
who 9 12 487 490 O
have 13 17 491 495 O
participated 18 30 496 508 O
in 31 33 509 511 O
MK-3475 34 41 512 519 B-treatment
Merck 42 47 520 525 I-treatment
studies 48 55 526 533 I-treatment

Patients 0 8 534 542 O
who 9 12 543 546 O
have 13 17 547 551 O
received 18 26 552 560 O
a 27 28 561 562 O
live 29 33 563 567 B-treatment
vaccine 34 41 568 575 I-treatment
within 42 48 576 582 O
30 49 51 583 585 B-upper_bound
days 52 56 586 590 I-upper_bound
prior 57 62 591 596 I-upper_bound
to 63 65 597 599 O
the 66 69 600 603 O
first 70 75 604 609 O
dose 76 80 610 614 O
of 81 83 615 617 O
pembrolizumab 84 97 618 631 B-treatment

Patients 0 8 632 640 O
who 9 12 641 644 O
have 13 17 645 649 O
received 18 26 650 658 O
chemotherapy 27 39 659 671 B-treatment
, 39 40 671 672 O
small 41 46 673 678 B-treatment
molecule 47 55 679 687 I-treatment
targeted 56 64 688 696 I-treatment
therapy 65 72 697 704 I-treatment
or 73 75 705 707 O
radiation 76 85 708 717 B-treatment
within 86 92 718 724 O
the 93 96 725 728 O
2 97 98 729 730 B-upper_bound
weeks 99 104 731 736 I-upper_bound
of 105 107 737 739 O
first 108 113 740 745 O
dose 114 118 746 750 O
of 119 121 751 753 O
study 122 127 754 759 B-treatment
drugs 128 133 760 765 I-treatment

Patients 0 8 766 774 O
who 9 12 775 778 O
have 13 17 779 783 O
received 18 26 784 792 O
monoclonal 27 37 793 803 B-treatment
anti 38 42 804 808 I-treatment
- 42 43 808 809 I-treatment
cancer 43 49 809 815 I-treatment
antibody 50 58 816 824 I-treatment
within 59 65 825 831 O
4 66 67 832 833 B-upper_bound
weeks 68 73 834 839 I-upper_bound
of 74 76 840 842 O
first 77 82 843 848 O
dose 83 87 849 853 O
of 88 90 854 856 O
study 91 96 857 862 O
drugs 97 102 863 868 O

Patients 0 8 869 877 O
with 9 13 878 882 O
a 14 15 883 884 O
known 16 21 885 890 O
additional 22 32 891 901 O
malignancy 33 43 902 912 B-cancer
that 44 48 913 917 O
is 49 51 918 920 O
progressing 52 63 921 932 O
or 64 66 933 935 O
requires 67 75 936 944 O
active 76 82 945 951 B-treatment
treatment 83 92 952 961 I-treatment
( 93 94 962 963 O
within 94 100 963 969 O
the 101 104 970 973 O
last 105 109 974 978 B-upper_bound
5 110 111 979 980 I-upper_bound
years 112 117 981 986 I-upper_bound
) 117 118 986 987 O

Patients 0 8 988 996 O
with 9 13 997 1001 O
carcinomatous 14 27 1002 1015 B-cancer
meningitis 28 38 1016 1026 I-cancer

Patients 0 8 1027 1035 O
with 9 13 1036 1040 O
chronic 14 21 1041 1048 B-chronic_disease
autoimmune 22 32 1049 1059 I-chronic_disease
disease 33 40 1060 1067 I-chronic_disease

Patients 0 8 1068 1076 O
with 9 13 1077 1081 O
conditions 14 24 1082 1092 O
requiring 25 34 1093 1102 O
immunosuppressive 35 52 1103 1120 B-treatment
medications 53 64 1121 1132 I-treatment
or 65 67 1133 1135 O
chronic 68 75 1136 1143 B-chronic_disease
infections 76 86 1144 1154 I-chronic_disease
( 87 88 1155 1156 O
including 88 97 1156 1165 O
HIV 98 101 1166 1169 B-chronic_disease
infection 102 111 1170 1179 I-chronic_disease
, 111 112 1179 1180 O
hepatitis 113 122 1181 1190 B-chronic_disease
B 123 124 1191 1192 I-chronic_disease
and 125 128 1193 1196 I-chronic_disease
C 129 130 1197 1198 I-chronic_disease
) 130 131 1198 1199 O

Patients 0 8 1200 1208 O
with 9 13 1209 1213 O
evidence 14 22 1214 1222 O
of 23 25 1223 1225 O
active 26 32 1226 1232 O
, 32 33 1232 1233 O
non 34 37 1234 1237 O
- 37 38 1237 1238 O
infectious 38 48 1238 1248 O
pneumonia 49 58 1249 1258 B-chronic_disease

Patients 0 8 1259 1267 O
with 9 13 1268 1272 O
prior 14 19 1273 1278 B-treatment
therapy 20 27 1279 1286 I-treatment
with 28 32 1287 1291 O
antibodies 33 43 1292 1302 B-treatment
that 44 48 1303 1307 I-treatment
modulate 49 57 1308 1316 I-treatment
T 58 59 1317 1318 I-treatment
- 59 60 1318 1319 I-treatment
cell 60 64 1319 1323 I-treatment
function 65 73 1324 1332 I-treatment
( 74 75 1333 1334 O
e.g. 75 79 1334 1338 O
, 79 80 1338 1339 O
anti 81 85 1340 1344 B-treatment
- 85 86 1344 1345 I-treatment
PD-1 86 90 1345 1349 I-treatment
, 90 91 1349 1350 O
anti 92 96 1351 1355 B-treatment
- 96 97 1355 1356 I-treatment
PD 97 99 1356 1358 I-treatment
- 99 100 1358 1359 I-treatment
L1 100 102 1359 1361 I-treatment
) 102 103 1361 1362 O

Platelet 0 8 1363 1371 B-clinical_variable
count 9 14 1372 1377 I-clinical_variable
≥ 15 16 1378 1379 O
100,000 17 24 1380 1387 B-lower_bound
/ 24 25 1387 1388 I-lower_bound
μL 25 27 1388 1390 I-lower_bound

Serum 0 5 1391 1396 B-clinical_variable
creatinine 6 16 1397 1407 I-clinical_variable
≤ 17 18 1408 1409 O
1.5 19 22 1410 1413 B-upper_bound
normal 23 29 1414 1420 I-upper_bound
institutional 30 43 1421 1434 I-upper_bound
limits 44 50 1435 1441 I-upper_bound

Subjects 0 8 1442 1450 O
must 9 13 1451 1455 O
have 14 18 1456 1460 O
received 19 27 1461 1469 O
no 28 30 1470 1472 O
more 31 35 1473 1477 O
than 36 40 1478 1482 O
2 41 42 1483 1484 B-upper_bound
prior 43 48 1485 1490 I-upper_bound
therapies 49 58 1491 1500 B-treatment
for 59 62 1501 1504 O
this 63 67 1505 1509 O
disease 68 75 1510 1517 O

Subjects 0 8 1518 1526 O
with 9 13 1527 1531 O
radiographically 14 30 1532 1548 O
stable 31 37 1549 1555 O
treated 38 45 1556 1563 O
brain 46 51 1564 1569 B-cancer
metastases 52 62 1570 1580 I-cancer

Subjects 0 8 1581 1589 O
with 9 13 1590 1594 O
uncontrolled 14 26 1595 1607 O
intercurrent 27 39 1608 1620 B-chronic_disease
illness 40 47 1621 1628 I-chronic_disease
including 48 57 1629 1638 O
, 57 58 1638 1639 O
but 59 62 1640 1643 O
not 63 66 1644 1647 O
limited 67 74 1648 1655 O
to 75 77 1656 1658 O
ongoing 78 85 1659 1666 O
or 86 88 1667 1669 O
active 89 95 1670 1676 B-chronic_disease
infection 96 105 1677 1686 I-chronic_disease
, 105 106 1686 1687 O
symptomatic 107 118 1688 1699 O
congestive 119 129 1700 1710 B-chronic_disease
heart 130 135 1711 1716 I-chronic_disease
failure 136 143 1717 1724 I-chronic_disease
, 143 144 1724 1725 O
unstable 145 153 1726 1734 B-chronic_disease
angina 154 160 1735 1741 I-chronic_disease
pectoris 161 169 1742 1750 I-chronic_disease
, 169 170 1750 1751 O
cardiac 171 178 1752 1759 B-chronic_disease
arrhythmia 179 189 1760 1770 I-chronic_disease
, 189 190 1770 1771 O
or 191 193 1772 1774 O
psychiatric 194 205 1775 1786 B-chronic_disease
illness 206 213 1787 1794 I-chronic_disease
/ 213 214 1794 1795 I-chronic_disease
social 214 220 1795 1801 I-chronic_disease
situations 221 231 1802 1812 I-chronic_disease
that 232 236 1813 1817 O
would 237 242 1818 1823 O
limit 243 248 1824 1829 O
compliance 249 259 1830 1840 O
with 260 264 1841 1845 O
study 265 270 1846 1851 O
requirements 271 283 1852 1864 O

Total 0 5 1865 1870 B-clinical_variable
bilirubin 6 15 1871 1880 I-clinical_variable
within 16 22 1881 1887 O
normal 23 29 1888 1894 O
institutional 30 43 1895 1908 O
limits 44 50 1909 1915 O

basal 0 5 1916 1921 B-cancer
cell 6 10 1922 1926 I-cancer
carcinoma 11 20 1927 1936 I-cancer
of 21 23 1937 1939 O
the 24 27 1940 1943 O
skin 28 32 1944 1948 O

must 0 4 1949 1953 O
not 5 8 1954 1957 O
have 9 13 1958 1962 O
been 14 18 1963 1967 O
on 19 21 1968 1970 O
steroid 22 29 1971 1978 B-treatment
therapy 30 37 1979 1986 I-treatment
for 38 41 1987 1990 O
at 42 44 1991 1993 O
least 45 50 1994 1999 O
4 51 52 2000 2001 B-lower_bound
weeks 53 58 2002 2007 I-lower_bound

willing 0 7 2008 2015 O
to 8 10 2016 2018 O
undergo 11 18 2019 2026 O
a 19 20 2027 2028 O
preliminary 21 32 2029 2040 O
biopsy 33 39 2041 2047 O
of 40 42 2048 2050 O
a 43 44 2051 2052 O
metastatic 45 55 2053 2063 B-cancer
focus 56 61 2064 2069 O
for 62 65 2070 2073 O
research 66 74 2074 2082 O
purposes 75 83 2083 2091 O

